1. Schechter AL, Stern DF, Vaidyanathan L et al. The neu oncogene: an ERB-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984; 312(5994): 513–516. 2. Finkle D, Quan ZR, Asghari V et al. HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res 2004; 10(7): 2499–2511. 3. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235(4785): 177–182. 4. Mishra R, Hanker AB, Garrett JT. Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget 2017; 8(69): 114371–114392. 5. Pillai RN, Behera M, Berry LD et al. HER2 mutations in lung adenocarcinomas: a report from the Lung Cancer Mutation Consortium. Cancer 2017; 123(21): 4099–4105. 6. Li BT, Ross DS, Aisner DL et al. HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers. J Thorac Oncol 2016; 11(3): 414–419. 7. Liu L, Shao X, Gao W et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol 2010; 5(12): 1922–1932. 8. Nakamura H, Saji H, Ogata A et al. Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in nonsmall cell lung cancer. Int J Cancer 2003; 103(1): 61–66. 9. Yoshizawa A, Sumiyoshi S, Sonobe M et al. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations. Lung Cancer 2014; 85(3): 373–378. 10. Peters S, Stahel R, Bubendorf L et al. Trastuzumab emtansine (T-DM1) in patients with previously treated HER2-overexpressing metastatic nonsmall cell lung cancer: efficacy, safety, and biomarkers. Clin Cancer Res 2019; 25(1): 64–72. 11. Dong ZY, Zhang JT, Liu SY et al. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. Oncoimmunology 2017; 6(11): e1356145. 12. Li BT, Shen R, Buonocore D et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a Phase II Basket Trial. J Clin Oncol 2018; 36(24): 2532–2537. 13. Hotta K, Aoe K, Kozuki T et al. A phase II study of trastuzumab emtansine in HER2-positive non-small cell lung cancer. J Thorac Oncol 2018; 13(2): 273–279. 14. Mazières J, Barlesi F, Filleron T et al. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann Oncol 2016; 27(2): 281–286. 15. Langer CJ, Stephenson P, Thor A et al. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group Study 2598. J Clin Oncol 2004; 22(7): 1180–1187. 16. Gatzemeier U, Groth G, Butts C et al. Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 2004; 15(1): 19–27. 17. Mazières J, Peters S, Lepage B et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013; 31(16): 1997–2003. 18. Hainsworth JD, Meric-Bernstam F, Swanton C et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from mypathway, an open-label, phase IIa multiple basket study. J Clin Oncol 2018; 36(6): 536–542. 19. Kris MG, Camidge DR, Giaccone G et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol 2015; 26(7): 1421–1427. 20. Hyman DM, Piha-Paul SA, Won H et al. HER kinase inhibition in patients with HER2and HER3-mutant cancers. Nature 2018; 554(7691): 189–194. 21. Gandhi L, Besse B, Mazieres J et al. MA04.02 neratinib 6 temsirolimus in HER2-mutant lung cancers: an international, randomized phase II study. J Thoracic Oncol 2017; 12(1): S358–S359. 22. De Grève J, Moran T, Graas MP et al. Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. Lung Cancer 2015; 88(1): 63–69. 23. Smit EF, Peters S, Dziadziuszko R et al. A single-arm phase II trial of afatinib in pretreated patients with advanced NSCLC harboring a HER2 mutation: the ETOP NICHE trial. J Clin Oncol 2017; 35(Suppl 15): 9070. 24. Lai W-CV, Lebas L, Milia J et al. Afatinib in patients with metastatic HER2-mutant lung cancers: an international multicenter study. J Clin Oncol 2017; 35(Suppl 15): 9071. 25. Wang Y, Jiang T, Qin Z et al. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. Ann Oncol 2019; 30(3): 447–455. 26. de Melo Gagliato D, Jardim DL, Marchesi MS, Hortobagyi GN. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2þ breast cancer. Oncotarget 2016; 7(39): 64431–64446. 27. Pauli C, Hopkins BD, Prandi D et al. Personalized. Cancer Discov 2017; 7(5): 462–477.

Chris Boshoff, Senior Vice President of Immuno-Oncology, Translational and Early Development at Pfizer, and colleagues Samra Turajlic and Charles Swanton from the Francis Crick Institute and University College London give us their personal point of view on new insights and future therapeutic approaches for renal cancer.

Immune-checkpoint inhibitors (ICPIs), including antibodies against cytotoxic T-lymphocyte associated antigen 4 and programmed cell death protein 1, have been shown to induce durable complete responses in a proportion of patients in the first-line and refractory setting in advanced melanoma and renal cell carcinoma. In fact, there are several lines of both targeted agents and ICPI that are now feasible treatment options. However, survival in the metastatic setting continues to be poor and there remains a need for improved therapeutic approaches. In order to enhance patient selection for the most appropriate next line of therapy, better predictive biomarkers of responsiveness will need to be developed in tandem with technologies to identify mechanisms of ICPI resistance. Adaptive, biomarker-driven trials will drive this evolution. The combination of ICPI with specific chemotherapies, targeted therapies and other immuno-oncology (IO) drugs in order to circumvent ICPI resistance and enhance efficacy is discussed. Recent data support the role for both targeted therapies and ICPI in the adjuvant setting of melanoma and targeted therapies in the adjuvant setting for renal cell carcinoma, which may influence the consideration of treatment on subsequent relapse. Approaches to select the optimal treatment sequences for these patients will need to be refined.